Skip to main content
PepStack
Hormone · Profile

Finasteride

Propecia · Proscar · 5-alpha reductase inhibitor

Hormone ManagementApproved
MW
372.5g/mol
Formula
C23H36N2O2

Finasteride is a synthetic 5α-reductase inhibitor primarily produced in the liver, which functions by blocking the conversion of testosterone to dihydrotestosterone (DHT), a potent androgen. Researchers primarily study finasteride for its effects on androgenetic alopecia (AGA) and benign prostatic hyperplasia. Clinical evidence indicates that finasteride can significantly increase hair count in men with AGA, while also being associated with sexual dysfunction and potential psychiatric side effects, including depression. Furthermore, studies suggest that the incidence of these adverse effects can persist even after discontinuation of the drug. Current research continues to explore the balance between its efficacy and safety, particularly in the context of long-term use and alternative formulations such as topical applications.

Overview

Übersicht

Finasteride is a synthetic compound classified as a 5-alpha reductase inhibitor. It is not an endogenous hormone but is chemically synthesized for therapeutic use. Finasteride is primarily used in the management of androgen-dependent conditions such as male androgenetic alopecia (AGA) and benign prostatic hyperplasia (BPH). It is available in oral formulations, commonly known under brand names like Propecia and Proscar. Researchers have focused on its ability to inhibit the conversion of testosterone to dihydrotestosterone (DHT), a potent androgen involved in hair loss and prostate enlargement. Finasteride's primary physiological role is to reduce DHT levels, which has been shown to improve hair count in AGA and reduce prostate size in BPH. Research areas include its efficacy in hair regrowth, impact on prostate health, and associated side effects. The mechanism of action involves the selective inhibition of the 5-alpha reductase type II enzyme, which is responsible for converting testosterone into DHT. This inhibition leads to a decrease in DHT levels both systemically and locally in tissues such as the scalp and prostate. Pharmacokinetically, finasteride has an oral bioavailability and a plasma half-life of approximately 4.5 hours. It is metabolized in the liver and excreted through urine and feces. Clinically, finasteride is approved by the FDA for the treatment of male AGA and BPH. It is generally well-tolerated, though researchers have observed side effects including sexual dysfunction and potential neuropsychiatric effects such as depression. Regulatory bodies have included warnings about these side effects in product labeling.

Chemical profile

Chemische Struktur

Chemical structure of Finasteride
FormelC23H36N2O2
Molekulargewicht372.5g/mol
CAS-Nummer98319-26-7
PubChem CID57363
Mechanism

Wirkmechanismus

Finasteride acts by inhibiting the 5-alpha reductase type II enzyme, reducing the conversion of testosterone to dihydrotestosterone (DHT). This leads to decreased DHT levels, which helps in reducing hair loss and prostate enlargement by mitigating the effects of this potent androgen.

Mechanism

Signalweg

Finasteride acts as a competitive inhibitor of the 5α-reductase (5AR) enzyme, specifically the type II isoenzyme, which catalyzes the conversion of testosterone to dihydrotestosterone (DHT), a potent androgen that binds to androgen receptors and activates androgen receptor signaling pathways. By reducing DHT levels, finasteride disrupts the signaling that promotes hair follicle miniaturization and androgen-dependent hair loss processes in androgenetic alopecia. The exact mechanisms underlying the adverse effects, including sexual dysfunction and potential neuropsychiatric impacts, are not fully understood.

Half-Life & Pharmacokinetics

POOral

Plasma half-life is approximately 4.5 hours

Finasteride is primarily administered orally. It undergoes hepatic metabolism and is excreted via urine and feces.

Storage

Temperature

Store at room temperature (15-30C)

Light

Protect from light

Form

Stable in tablet form

Notes

Ensure packaging is sealed to prevent moisture exposure.

Solubility

Löslichkeit

Finasteride is poorly soluble in water but soluble in ethanol and chloroform.

Legal Status

🇩🇪DE

Prescription only (verschreibungspflichtig). Not a controlled substance under BtMG.

🇺🇸US

FDA approved for AGA and BPH. Prescription required.

🇦🇺AU

Schedule 4 (S4) prescription-only medicine.

🇬🇧UK

Prescription only medicine (POM) under MHRA regulations.

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

Open Questions

Offene Forschungsfragen

Current evidence is limited regarding the long-term psychiatric effects of finasteride, particularly the persistence of depression and suicidal ideation after discontinuation, necessitating larger longitudinal studies to clarify these associations. Additionally, while topical finasteride shows promise in reducing systemic side effects, further research is needed to evaluate its long-term efficacy and safety compared to oral formulations in diverse populations, including women and different age groups. There is also a need for more comprehensive studies examining the sexual side effects across various dosages and formulations of finasteride and dutasteride to better understand the risk factors and mechanisms involved.

63 Research Publications

4,458

Total Citations

24

Human/RCT

6.7

Avg. Influence

2023

Latest

Sort
Filter
#01

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

HumanInfluence88.0
1884
The study demonstrated that long-term finasteride treatment significantly reduced the risk of clinical progression of benign prostatic hyperplasia compared to placebo.
#02

Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group.

Kaufman K D, et al. · Journal of the American Academy of Dermatology · 1998

HumanInfluence18.0
604
The study demonstrated that finasteride 1 mg/day significantly improved scalp hair counts in men with male pattern hair loss over two years compared to placebo.

Key findings

  1. 01Finasteride treatment led to a significant increase in hair count after one and two years.
  2. 02Men taking finasteride reported improvements in hair growth and appearance.
  3. 03Minimal adverse effects were noted during the study.
#03

The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.

HumanInfluence12.0
207
Researchers observed that finasteride significantly reduced scalp and serum DHT levels in men with androgenetic alopecia, supporting its efficacy in hair loss management.
#04

Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects.

Case ReportInfluence7.0
167
The study demonstrated that former users of finasteride with persistent sexual side effects exhibited significantly higher rates of depressive symptoms and suicidal thoughts compared to controls.
#05

Clinical pharmacokinetics and pharmacodynamics of finasteride.

ReviewInfluence6.0
114
Researchers observed that finasteride significantly reduces dihydrotestosterone levels and prostate size, but the correlation with symptom improvement in benign prostatic hyperplasia is limited.
#06

Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.

Piraccini B M, et al. · Journal of the European Academy of Dermatology and Venereology : JEADV · 2022

HumanInfluence6.0
112
Researchers observed that topical finasteride significantly improved hair count compared to placebo, with a safety profile similar to oral finasteride but with lower systemic exposure.

Key findings

  1. 01Topical finasteride increased hair count more than placebo after 24 weeks.
  2. 02The side effects of topical finasteride were similar to those of the placebo.
  3. 03Topical finasteride had much lower levels of systemic exposure than oral finasteride.
#07

Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia.

Gupta Aditya K, et al. · The Journal of dermatological treatment · 2022

ReviewInfluence9.0
96
Researchers observed that dutasteride was more effective than finasteride for androgenetic alopecia, with both drugs exhibiting similar safety profiles.

Key findings

  1. 01Dutasteride is probably the most effective treatment for androgenetic alopecia.
  2. 02Finasteride is FDA-approved, while minoxidil and dutasteride are used off-label.
  3. 03Minoxidil can cause excessive hair growth and cardiovascular issues, while finasteride and dutasteride may lead to sexual side effects.
#08

Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride.

Case ReportInfluence5.0
92
Researchers observed significant signals for suicidality and psychological adverse events associated with finasteride use, particularly in younger patients with alopecia.
#09

Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers.

Human
77
Researchers observed that finasteride significantly reduces serum dihydrotestosterone levels compared to placebo, confirming its efficacy as a 5-alpha reductase inhibitor in healthy male volunteers.
#10

Finasteride for hair loss: a review.

Gupta A K, et al. · The Journal of dermatological treatment · 2022

HumanInfluence2.0
76
The study demonstrated that finasteride 1 mg/day significantly increased total hair count compared to placebo after 24 and 48 weeks, while also highlighting common sexual side effects.

Key findings

  1. 01Finasteride 1 mg/day significantly increases total hair count after 24 weeks.
  2. 02The review covers how finasteride functions and is processed in the body.
  3. 03Potential side effects and post-marketing reports were also discussed.

Clinical Trials (50)

Preclinical
Phase I
Phase II
Phase III
Approved

50

Total Trials

61,239

Total Enrolled

Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Validation Study Linking Adherence to Outcomes Using the Market Scan Database

NCT01381510COMPLETED
Sponsor

GlaxoSmithKline

Enrollment

54,459

Started

2010

Primary outcome

The occurence of a diagnosis code for acute urinary retention (AUR) or a procedure code for prostate surgery

Prostatic Hyperplasia

Topical Finasteride in the Treatment of Idiopathic Hirsutism

NCT00564252COMPLETED
Sponsor

Iran University of Medical Sciences

Enrollment

56

Started

2006

Primary outcome

the efficacy of topical finasteride was determined by comparison of Ferriman-Gallwey score before and after medication

Idiopathic Hirsutism

High Risk Prostate Cancer Prevention Study

NCT01174953COMPLETED
Sponsor

University of Kansas

Enrollment

18

Started

2010

Primary outcome

Biomarkers will be identified to help predict future prostate cancer risks and patients likely to benefit from preventive strategies

Prostate Cancer

Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients

NCT01736033Phase 4UNKNOWN
Sponsor

Seoul National University Hospital

Enrollment

545

Started

2012

Primary outcome

Clinical Progression

Benign Prostate Hyperplasia

Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) Patients

NCT02244229Phase 4COMPLETED
Sponsor

Boehringer Ingelheim

Enrollment

403

Started

1998

Primary outcome

Change from baseline in Symptom Problem Index (SPI) by means of validated patient questionnaire

Prostatic Hyperplasia

3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer

NCT01296672Phase 4COMPLETED
Sponsor

The University of Texas Health Science Center at San Antonio

Enrollment

383

Started

2011

Primary outcome

Pre/Post Ratio PSA Area Under the Curve (AUC)

Prostate Cancer

Effect of Different Dosing Regimens of Tadalafil or Tamsulosin Combined With 5α-Reductase Inhibitors on Urinary and Sexual Outcomes in Benign Prostatic Hyperplasia

NCT07715448Phase 4COMPLETED
Sponsor

Beni-Suef University

Enrollment

240

Primary outcome

Change in Lower Urinary Tract Symptoms (IPSS)

Benign Prostatic HyperplasiaLower Urinary Tract SymptomsErectile Dysfunction

Kinetics of the Finasteride Prostate Induced Apoptosis

NCT00130767Phase 4UNKNOWN
Sponsor

Hospices Civils de Lyon

Enrollment

90

Started

2004

Primary outcome

Date of the maximum apoptosis in the prostate tissues treated by finasteride

Benign Prostatic Hyperplasia

Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia

NCT01231607Phase 3COMPLETED
Sponsor

GlaxoSmithKline

Enrollment

917

Started

2010

Primary outcome

Change From Baseline (BL) in Target Area Hair Count (HC) Within a 2.54 Centimeter (cm) (1 Inch) Diameter Circle at the Vertex at Week 24, as Assessed by Macrophotographic Technique (MT)

Androgenetic Alopecia

A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)

NCT00127179Phase 3COMPLETED
Sponsor

Organon and Co

Enrollment

600

Started

2004

Primary outcome

Change from baseline in the International Prostate Symptom Score

Benign Prostatic Hyperplasia

Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia

NCT03004469Phase 3COMPLETED
Sponsor

Polichem S.A.

Enrollment

458

Started

2016

Primary outcome

Adjusted Mean Change From Baseline in Hair Growth Assessed by Target Area Hair Count (TAHC) in the Vertex at Week 24

Alopecia, Androgenetic

Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)

NCT04032067Phase 3COMPLETED
Sponsor

GemVax & Kael

Enrollment

423

Started

2019

Primary outcome

Change in International Prostate Symptom Score(IPSS)

Benign Prostatic Hyperplasia (BPH)

Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111)

NCT00396175Phase 3COMPLETED
Sponsor

Organon and Co

Enrollment

355

Started

1998

Primary outcome

Serum Prostatic Specific Antigen (PSA) after 48 weeks of treatment

Androgenetic Alopecia

Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia

NCT04594018Phase 3RECRUITING
Sponsor

EMS

Enrollment

190

Started

2023

Primary outcome

Change from baseline in hair density.

Androgenetic Alopecia

Minimally Invasive Surgical Therapy for BPH

NCT00064649Phase 3TERMINATED
Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Enrollment

49

Started

2004

Benign Prostatic Hyperplasia

Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss

NCT01391156Phase 3COMPLETED
Sponsor

Mae Fah Luang University Hospital

Enrollment

40

Started

2011

Primary outcome

The mean change of hair count from baseline and 6 months

Androgenetic Alopecia

A Trial of PROSCAR (Finasteride) Versus Placebo in Men With an Initial Negative Prostate Biopsy

NCT00542243Phase 3COMPLETED
Sponsor

University Health Network, Toronto

Enrollment

19

Started

2008

Primary outcome

The rate of prostate cancer at repeat TRUS (Transrectal Ultrasound) guided biopsy after 6 months of therapy with Finasteride/placebo.

Enlarged Prostate

Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)

NCT01534351Phase 3TERMINATED
Sponsor

Merck Sharp & Dohme LLC

Enrollment

1

Started

2013

Primary outcome

Change From Baseline in International Prostate Symptom Score (IPSS)

Benign Prostatic Hyperplasia

Finasteride and Flutamide in Pre-surgical Trial in Prostate Cancer.

NCT06601205Phase 2/3COMPLETED
Sponsor

Ente Ospedaliero Ospedali Galliera

Enrollment

125

Started

2004

Primary outcome

Change of Nuclear area size

Prostate CancerProstatic Intraepithelial Neoplasia

Effectiveness and Safety of Topical Finasteride and Minoxidil Combination Compared to Topical Minoxidil for The Treatment of Male Androgenetic Alopecia

NCT05990400Phase 2/3UNKNOWN
Sponsor

Indonesia University

Enrollment

40

Started

2023

Primary outcome

Hair density

Androgenetic Alopecia

New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia

NCT06944145Phase 2RECRUITING
Sponsor

Beth Israel Deaconess Medical Center

Enrollment

242

Started

2025

Primary outcome

Clinical response to at 12 months after study enrollment

BPH (Benign Prostatic Hyperplasia)Lower Urinary Track Symptoms

Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery

NCT00438464Phase 2COMPLETED
Sponsor

National Cancer Institute (NCI)

Enrollment

204

Started

2007

Primary outcome

Comparison of Biomarkers Between Treatment Arms: Percentage Change of Tumor Cells Exhibiting Detectable Staining Within Gleason Grade 3 (GG3) Biomarker Subgroups at Prostatectomy

Adenocarcinoma of the ProstateStage II Prostate Cancer

Various Procedural Treatment Options for Androgenetic Alopecia

NCT06826001Phase 2NOT_YET_RECRUITING
Sponsor

Sheikh Zayed Medical College

Enrollment

190

Started

2025

Primary outcome

COMPARISON OF EFFICACY OF TOPICAL FINESTERIDE VERSUS TOPICAL MINOXIDAL IN TREATMENT OF ANDROGENETIC ALOPECIA

Androgenetic Alopecia

A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males

NCT02781311Phase 2COMPLETED
Sponsor

Allergan

Enrollment

169

Started

2016

Primary outcome

Change From Baseline in Target Area Hair Count (TAHC) at Week 24

Alopecia

Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia

NCT07076706Phase 2COMPLETED
Sponsor

Beijing Dayspring Pharmaceutical Technology Co., Ltd

Enrollment

110

Started

2024

Primary outcome

Change from baseline in the non-vellus target area hair count(TAHC) at 24 weeks

Male Pattern of Hair Loss, Androgenic AlopeciaAndrogenetic Alopecia (AGA)

Finasteride Treatment of Severe Nodulocystic Acne

NCT02502669Phase 2COMPLETED
Sponsor

Elorac, Inc.

Enrollment

106

Started

2015

Primary outcome

Acne Nodular Lesion Count

NODULOCYSTIC ACNE

Hormone Therapy in Treating Patients With Prostate Cancer

NCT00003323Phase 2COMPLETED
Sponsor

Alliance for Clinical Trials in Oncology

Enrollment

101

Started

1998

Primary outcome

PSA levels

Prostate CancerSexual Dysfunction and Infertility

Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)

NCT00759135Phase 2COMPLETED
Sponsor

Nymox Corporation

Enrollment

85

Started

2007

Primary outcome

Change in BPH Symptom Score (AUA SI)

Benign Prostatic Hyperplasia (BPH)Enlarged Prostate

5-Alpha Reductase and Anabolic Effects of Testosterone

NCT00475501Phase 2COMPLETED
Sponsor

VA Office of Research and Development

Enrollment

60

Started

2007

Primary outcome

1 Repetition Maximum (1-RM) Strength Testing

Male HypogonadismMuscle AtrophySarcopeniaBenign Prostate Hypertrophy

Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.

NCT02213107Phase 2COMPLETED
Sponsor

University of Rochester

Enrollment

43

Started

2014

Primary outcome

Prostate Specific Antigen (PSA) Progression Free Survival

Prostate Cancer

Testosterone Plus Finasteride Treatment After Spinal Cord Injury

NCT02248701Phase 2TERMINATED
Sponsor

VA Office of Research and Development

Enrollment

33

Started

2017

Primary outcome

Percent Change in Hip Bone Mineral Density

Spinal Cord InjurySpinal Cord InjuriesTrauma, Nervous SystemWounds and InjuriesCentral Nervous System DiseasesNervous System DiseasesSpinal Cord DiseasesGonadal DisordersEndocrine System DiseasesHypogonadismGenital Diseases, Male

The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy

NCT00600691Phase 2TERMINATED
Sponsor

University of British Columbia

Enrollment

29

Started

2008

Primary outcome

Differences in rate and severity of hematuria and hematospermia among subjects in treatment and placebo groups.

HematuriaHematospermia

Finasteride, Dutasteride and Insulin Action

NCT01923090Phase 2UNKNOWN
Sponsor

University of Birmingham

Enrollment

12

Started

2012

Primary outcome

insulin sensitivity

Healthy Volunteers

Finasteride for Chronic Central Serous Chorioretinopathy

NCT01585441Phase 2TERMINATED
Sponsor

National Eye Institute (NEI)

Enrollment

6

Started

2012

Primary outcome

Proportion of Participants With an Improvement in Best-corrected Visual Acuity (BCVA) ≥ 15 Letters at 3 Months Compared to Baseline.

Retinal Disease

Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer

NCT02055170Phase 2TERMINATED
Sponsor

CancerCare Manitoba

Enrollment

4

Started

2014

Primary outcome

Change in proliferation

Non-small Cell Lung Cancer

A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001

NCT04945226Phase 1/2COMPLETED
Sponsor

Inventage Lab., Inc.

Enrollment

40

Started

2021

Primary outcome

AUClast of IVL3001

Androgenetic Alopecia

Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy

NCT00837252Phase 1/2COMPLETED
Sponsor

National Eye Institute (NEI)

Enrollment

5

Started

2009

Primary outcome

Change in Visual Acuity at Month 3 Compared to Baseline.

Retinal Disease

Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy

NCT01227993Phase 1/2COMPLETED
Sponsor

National Eye Institute (NEI)

Enrollment

3

Started

2010

Primary outcome

Change in Best-corrected Visual Acuity (BCVA) in the Study Eye at Two Years Compared to Baseline

Retinal Disease

Study to Evaluate Safety & Usability of a New Formulation for Male Androgenetic Alopecia

NCT05611593Phase 1UNKNOWN
Sponsor

Follicle Pharma Ltd

Enrollment

90

Started

2022

Primary outcome

Safety of product application

Androgenic Alopecia

Study to Evaluate the Drug-drug Interaction Between IY001 and IY002 in Healthy Adult Male Subjects.

NCT07322991Phase 1COMPLETED
Sponsor

Il-Yang Pharm. Co., Ltd.

Enrollment

43

Started

2025

Primary outcome

Finasteride Area Under the Curve during the dosing interval at steady state (AUCτ,ss)

Healthy Adult Male

Finasteride 5 mg Tablets Under Fasting Conditions

NCT00835666Phase 1COMPLETED
Sponsor

Teva Pharmaceuticals USA

Enrollment

32

Started

2002

Primary outcome

Cmax - Maximum Observed Concentration

Healthy

Fed Study of Finasteride Tablets 5 mg and Proscar® Tablets 5 mg

NCT00650377Phase 1COMPLETED
Sponsor

Mylan Pharmaceuticals Inc

Enrollment

30

Started

2004

Primary outcome

Bioequivalence

Healthy

Fasting Study of Finasteride Tablets 5 mg and Proscar Tablets 5 mg

NCT00648791Phase 1COMPLETED
Sponsor

Mylan Pharmaceuticals Inc

Enrollment

29

Started

2004

Primary outcome

Bioequivalence

Healthy

Bioequivalence Study of Two Finasteride 5 mg Tablet Formulations Under Non-Fasting Conditions

NCT01264302Phase 1COMPLETED
Sponsor

Dr. Reddy's Laboratories Limited

Enrollment

26

Started

2006

Primary outcome

Bioequivalence based on Cmax and AUC parameters

Healthy

Bioequivalence Study of Finasteride 5 mg Tablet Formulations Under Fasting Conditions

NCT01264289Phase 1COMPLETED
Sponsor

Dr. Reddy's Laboratories Limited

Enrollment

26

Started

2006

Primary outcome

Bioequivalence based on Cmax and AUC parameters

Healthy

PK Comparison of GL2701 With Finasteride and Tamsulosin in Combination

NCT01829893Phase 1COMPLETED
Sponsor

Korea University Anam Hospital

Enrollment

26

Started

2012

Primary outcome

Finasteride and Tamsulosin pharmacokinetics (Cmax and AUC)

Benign Prostatic Hyperplasia (BPH)

A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Fed Conditions

NCT00871247Phase 1COMPLETED
Sponsor

Actavis Inc.

Enrollment

26

Started

2004

Primary outcome

Rate and Extend of Absorption

Healthy

A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Fasting Conditions

NCT00870480Phase 1COMPLETED
Sponsor

Actavis Inc.

Enrollment

26

Started

2004

Primary outcome

Rate and Extend of Absorption

Healthy

Finasteride 5 mg Tablets, Non-fasting

NCT00835796Phase 1COMPLETED
Sponsor

Teva Pharmaceuticals USA

Enrollment

20

Started

2002

Primary outcome

Cmax - Maximum Observed Concentration

Healthy

Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia

NCT01052870Phase 1COMPLETED
Sponsor

HairDx, LLC

Enrollment

12

Started

2008

Androgenetic Alopecia

Track your hormone research in PepStack

Log cycles, set reminders and visualize serum levels.

Legal Disclaimer

This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer